|
Mar 21
2011
|
Neurofibromatosis and CTF Spotlighted at Massachusetts Biotech MeetingPosted by: Kim Hunter-Schaedle on Mar 21, 2011 Tagged in: schwannomatosis , Research , Preclinical Drug Testing , NF2 , NF1 , Clinical Trials , Children's Tumor Foundation , Advocacy
|
|
Today I will attend the annual Massachusetts Biotech Meeting (Mass Bio) . This year's theme, 'Every Patient Tells a Story' speaks to the growing role of patients and their advocates, including foundations like the Children's Tumor Foundation that fund early stage research ideas, in providing a bridge between basic research and the pharmaceutical and biotechnology companies so that - in our case - we help drive progress toward the development of drug treatments for neurofibromatosis.
Today I will be presenting a poster 'Neurofibromatosis Networking' that showcases to potential industry collaborators all of the resources that CTF has developed to make neurofibromatosis drug development easier, including our NF Preclinical Consortium and 44-site NF Clinic Network which last year cared for 10,000 NF patients. Look out for updates from the meeting later this week!
Neurofibromatosis and CTF Spotlighted at Massachusetts Biotech Meeting





